Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIR-DIR
2025-522305-38-00Phase 2Authorised
- Sponsor
- University of Pécs
- Start
- Jul 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan, folinic acid and fluorouracil in metastatic colon cancer (mCRC) (2 arms), sponsored by University of Pécs. Primary endpoint: Progression-free survival. Planned start Jul 2025; status: authorised.
02
Drugs
irinotecanfolinic acidfluorouracil
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2025-522305-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522305-38-00.